

## **Antimicrobial resistance targets** -2024 update<sup>ii</sup>-



Luxemb	ourg
--------	------

	Lancinocai	Target :	achieved Progress	Regress
	Reduce by 18% the total consumption of antibiotics in humans	2019 baseline	21.1	-
		2023	20.2	-4.3%
	Defined daily doses (DDDs) per 1 000 inhabitants per day	2030 TARGET	17.3	-18%
	At least 65% of the total consumption of antibiotics in humans belongs to the 'Access' group of antibiotics  As defined in the AWaRe classification of the WHO	2019 baseline	59.5%	-
		2023	61.7%	+2.2%*
*Percentage point difference from 2019.		2030 TARGET	65%	+5.5%*
	Reduce by 6% the total incidence of bloodstream infections with meticillin-resistant <i>Staphylococcus aureus</i> (MRSA)	2019 baseline	2.1	-
		2023	1.7	-22.4%
	Number per 100 000 population	2030 TARGET	2.0	-6%
	Reduce by 12% the total incidence of bloodstream infections with third-generation cephalosporin-resistant <i>Escherichia coli</i> Number per 100 000 population	2019 baseline	10.2	-
		2023	8.2	-19.9%
		2030 TARGET	9.0	-12%
888	Reduce by 2% the total incidence of bloodstream infections with carbapenem-resistant <i>Klebsiella pneumoniae</i>	2019 baseline	0.16	-
		2023	0.30	+87.5%
	Number per 100 000 population	2030 TARGET	0.157	-2%

Council Recommendation targets on stepping up EU actions to combat antimicrobial resistance in a One Health approach (2023/C 220/01)